Population Council
Executive Summary
Organization begins Phase I trial of luteinizing hormone- releasing hormone (LHRH) hydrogel implant in 40 prostate cancer patients. The drug-release implant, which is being manufactured by the National Patent Development Corporation, delivers LHRH over the period of a year. The LHRH analog used in the Population Council's product is histrelin. The Population Council says that it intends to investigate the LHRH hydrogel implant in the future as a male contraceptive and for precocious puberty.